Researchers at Hokkaido University in Japan have demonstrated that a molecule, called biglycan, plays an intrinsic role in attracting
tumour cells toward the inner wall of tumour blood vessels.
«The cytotoxic chemotherapy can first kill some cancer
cells and enhance the sensitivity of the
tumour toward ICB therapy, which then stimulates the effectiveness of the ICB therapy,» said co-author Gianpietro Dotti, PhD, professor of microbiology and immunology at the UNC School of Medicine and member of the UNC Lineberger Comprehensive Cancer Center.